Mithra Pharmaceuticals S.A.
MITPFOTCHealthcare
$23.90
+$17.15(+254.07%)
Market Cap$1.6B
P/E Ratio—
52W High$23.9
52W Low$6.75
Mithra Pharmaceuticals S.A. (MITPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MITPF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $40.16M | $67.00M | $22.67M | $9.03M | $96.52M |
| Cost of Revenue | $34.16M | $31.56M | $26.15M | $13.33M | $8.26M |
| Gross Profit | $5.99M | $35.43M | ($3.48M) | ($4.30M) | $88.26M |
| Gross Margin %(computed) | 14.92% | 52.89% | -15.36% | -47.62% | 91.44% |
| Operating Expenses | |||||
| R&D Expenses | $63.17M | $64.04M | $85.24M | $78.46M | $57.07M |
| G&A Expenses | $22.09M | $14.68M | $12.52M | $15.93M | $14.77M |
| Total Operating Expenses | $75.31M | $68.88M | $89.20M | $85.95M | $67.84M |
| Operating Income | ($69.32M) | ($33.44M) | ($92.69M) | ($90.25M) | $20.42M |
| Operating Margin %(computed) | -172.63% | -49.92% | -408.88% | -999.48% | 21.15% |
| Interest Income | $1.75M | $14.03M | $11.77M | $3.50M | $3.32M |
| Interest Expense | $22.90M | $17.03M | $12.12M | $3.56M | $3.37M |
| Income Before Tax | ($161.79M) | ($13.56M) | ($126.34M) | ($112.79M) | ($33.01M) |
| Income Tax Expense | $11.71M | $46.06M | ($9.46M) | ($20.70M) | ($6.45M) |
| Net Income | ($173.50M) | ($59.62M) | ($116.88M) | ($92.09M) | ($26.56M) |
| Net Margin %(computed) | -432.08% | -88.99% | -515.59% | — | -27.52% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.51 | $-1.22 | $-2.69 | $-2.25 | $-0.70 |
| Wtd Avg Shares | 69.12M | 49.06M | 43.43M | 40.99M | 37.75M |
| EBITDA | ($52.77M) | $17.46M | ($82.26M) | ($80.38M) | $26.19M |
| EBITDA Margin %(computed) | -131.42% | 26.06% | -362.89% | -890.14% | 27.14% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · M
Explore more Mithra Pharmaceuticals S.A. data
About Mithra Pharmaceuticals S.A. (MITPF) Income Statement
Mithra Pharmaceuticals S.A. (MITPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, MITPF reported revenue of $0.04B, gross profit of $0.01B (gross margin 14.92%), and net income of ($0.17B) — a net profit margin of -432.08%.
Frequently asked questions
MITPF · 4 questionsMithra Pharmaceuticals S.A. (MITPF) reported revenue of $0.04B for 2023, down 40.1% year-over-year.
MITPF revenueMITPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08